StockNews.AI
BLFS
StockNews.AI
180 days

BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025

1. BLFS schedules Q4 and full-year financial results release on March 3, 2025. Investors can join a webcast and conference call. 2. Management to discuss performance and provide a general business update. Information is available on the investor website. 3. A replay of the webcast will be accessible two hours after the call. It will be archived online for 90 days.

-3.05%Current Return
VS
-1.72%S&P 500
$27.5102/20 04:21 PM EDTEvent Start

$26.6702/21 10:40 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

This is a routine earnings announcement that typically results in limited immediate price movement unless surprises occur. Historically, scheduled earnings calls create modest volatility without major directional change unless significant news is disclosed.

How important is it?

As a scheduled earnings announcement, the event is inherently important but typical in nature, limiting its overall surprise factor and impact on BLFS’s price.

Why Short Term?

Earnings results and business updates generally impact the stock price over the short term around the release date. Similar events in comparable companies have led to short-term trading adjustments.

Related Companies

, /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers.  A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days. About BioLife SolutionsBioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X. Media & Investor Relations At the CompanyTroy WichtermanChief Financial Officer(425) 402-1400[email protected] InvestorsAlliance Advisors IRJody Cain(310) 691-7100[email protected] SOURCE BioLife Solutions, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News